Company Profile

Certification


DOCETERE

 For Healthcare Professional Only

DOCETERE

Docetaxel trihydrate - Vial 20mg, Vial 80mg

Indications
Breast & nonsmall cell lung cancer.

Dosage
1 hr infusion every 3 wk. Locally advanced or metastatic breast cancer 100 mg/m2 IV over 1 hr every 3 wk, can be reduced to 60 or 75 mg/m2. 1st-line treatment of breast cancer 76 mg/m2 in combination w/ doxorubicin. In combination w/ capecitabine, 75 mg/m2 every 3 wk. Nonsmall cell lung cancer 75 mg/m2 IV over 1 hr immediately followed by cisplatin every 3 wk. Treatment after failure of platinum-based chemotherapy 75 mg/m2 IV over 1 hr every 3 wk.

Contraindications

Neutrophil count <1500 cell/mm3. Severe liver impairment. Pregnancy & lactation. Childn.

Special precautions
All patients must be premedicated w/ oral corticosteroids for 3 days prior to docetaxel chemotharapy. CBC monitoring, re-treatment for neutrophil level ≥1500 cells/mm3. Hypersensitivity & cutaneous reactions; pleural & pericardial effusion, ascites; severe peripheral neurotoxicity; asthenia; heart failure. Contraceptive measures should be taken during & for <3 mth after cessation of therapy. Liver impairment.

Adverse drug reactions

Reversible neutropenia, fluid retention, cardiac disorders, febrile neutropenia, sepsis, pneumonia, thrombocytopenia, bleeding episodes, anemia; peripheral edema, pleural & pericardial effusion, ascites, lacrimation, wt gain; flushing, rash, chest tightness, back pain, dyspnea, fever, chills; hypotension, bronchospasm, erythema; localized eruptions, stomatitis, diarrhea, nausea, vomiting, constipation, taste perversion, GI bleeding, abdominal pain; cardiac dysrhythmia, hypotension, HTN, lower limb edema; anorexia, decreased apetite, dehydration, decreased wt; myalgia, arthralgia, sore throat, cough, epistaxis; elevated bilirubin, alkaline phosphatase, AST & ALT levels.

For details information, please contact us at info@ferron-pharma.com